Ingrid V. Bassett, MD, MPH
Infectious Disease Unit at Massachusetts General Hospital. Associate Professor of Medicine at Harvard Medical School
Contact: email@example.com (617) 726-0637
Dr. Bassett focuses on innovative ways to screen for HIV and tuberculosis and to optimize linkage to care for these diseases in South Africa. She is PI of the multi-site Sizanani RCT (R01 MH090326) evaluating the efficacy of health system navigators for improving linkage to HIV care and tuberculosis treatment completion and the randomized pilot trial to assess the clinical impact of mobile, community-based GeneXpert MTB/RIF screening (R21AI110264). The tobacco use prevalence in these studies is 20-30%, which could provide a K12 scholar the opportunity to investigate the relationship between tobacco use and poorer outcomes of tuberculosis and HIV treatment. Dr. Bassett is an accomplished mentor who won the highly-competitive 2013 HMS Young Mentor Award and is Director of Mentoring Programs for the Harvard University Center for AIDS Research. She mentors three post-doctoral trainees and collaborates with Dr. Freedberg.
What happens after diagnosis: Characterizing long-term HIV care trajectories and mortality in South Africa
NIMH R01 MH108427 2016 – 20
The purpose of this project is to study long-term patterns of HIV care engagement and mortality, and the social, behavioral, and geographic factors that influence them. This work will inform physicians, policymakers, and governments on how to design interventions to maximize the long-term effectiveness of HIV treatment programs.
South Africa’s new central chronic medicine dispensing and distribution program: Assessing the clinic, patient, and community impact
ECOR Formulaic Bridge Funding MGH Executive Committee on Research
This project will comprehensively evaluate the impact of South Africa’s new Central Chronic Medicine Dispensing and Distribution (CCMDD) program at all 10 public sector clinics in Umlazi by: 1) Prospectively assessing patient uptake of CCMDD and patient factors associated with favorable early clinical outcomes for CCMDD enrollees and comparing outcomes with non-enrollees; 2) Evaluating facilitators of and barriers to adoption of CCMDD by patients, clinic staff, and administrators using qualitative methods, and 3) Evaluating virologic suppression over time across all 10 public sector clinics in Umlazi using programmatic electronic health record data.